	US 12,018,073 B2
	Antagonists targeting the TGF-β pathway
Margaret Karow, Santa Rosa Valley, CA (US); Jackie Sheng, Thousand Oaks, CA (US); and Wei Zhang, Thousand Oaks, CA (US)
Assigned to GENSUN BIOPHARMA, INC., Newbury Park, CA (US)
Filed by GENSUN BIOPHARMA, INC., Newbury Park, CA (US)
Filed on Aug. 17, 2020, as Appl. No. 16/995,428.
Application 16/995,428 is a continuation of application No. 16/706,187, filed on Dec. 6, 2019, granted, now 10,851,157.
Claims priority of provisional application 62/869,111, filed on Jul. 1, 2019.
Prior Publication US 2021/0002348 A1, Jan. 7, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/00 (2006.01); C07K 14/71 (2006.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01)

CPC C07K 16/22 (2013.01) [C07K 14/71 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 38/00 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/622 (2013.01); C07K 2317/66 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01)]

22 Claims

1. A protein comprising:

a first targeting domain comprising a mutated TGF-β1 RII extracellular domain (mutated ECD), wherein the mutated ECD comprises SEQ ID NO:89 with one or more substitutions and/or deletions that reduce proteolytic degradation or clipping; and

an immunoglobulin scaffold having an amino terminus and a carboxy terminus, and

wherein the mutated ECD comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 114-123 and 251-270.